Clinical Trial Update: A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating a novel anti-CD19 CAR-T therapy in patients with relapsed/refractory B-cell malignancies (leukemia and lymphoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma
• B-cell Tumors

Drugs mentioned

• Novel anti-CD19 CAR-T therapy

Snippet

Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Conditions: B-Cell Leukemia, B-Cell Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN